tiprankstipranks
Trending News
More News >
Catheter Precision (VTAK)
:VTAK

Catheter Precision (VTAK) AI Stock Analysis

Compare
428 Followers

Top Page

VT

Catheter Precision

(NYSE MKT:VTAK)

Rating:49Neutral
Price Target:
$0.50
▲(38.89%Upside)
The most significant factors impacting the score are the financial performance challenges and valuation concerns. While there is positive technical momentum and promising product sales, the risks associated with leadership changes and stock dilution weigh heavily on the overall outlook.

Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)

Catheter Precision Business Overview & Revenue Model

Company DescriptionCatheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
How the Company Makes MoneyCatheter Precision generates revenue primarily through the sale of its catheter-based medical devices to hospitals, clinics, and healthcare providers. The company may also engage in strategic partnerships with larger medical device firms to expand its market reach and distribution capabilities. Additionally, revenue streams could include licensing agreements for its proprietary technology and intellectual property, as well as potential service agreements for training and support related to the use of its products. The company’s earnings are influenced by factors such as the adoption rate of its technologies in healthcare facilities, the development of new products, and its ability to navigate regulatory approvals in various markets.

Catheter Precision Financial Statement Overview

Summary
VTAK's financial performance is weak, with significant challenges in profitability and cash flow. The income statement highlights declining revenue and operational losses. The balance sheet shows some financial stability due to equity financing, but ongoing negative cash flows and net losses are concerning.
Income Statement
20
Very Negative
The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.
Balance Sheet
40
Negative
The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.
Cash Flow
30
Negative
Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
481.00K420.00K442.00K14.00K22.00K4.41M
Gross Profit
433.00K378.00K412.00K-147.00K-1.54M-1.08M
EBIT
-12.19M-11.24M-78.12M-26.96M-29.27M-36.06M
EBITDA
-11.23M-11.30M-15.11M-22.37M-27.70M-33.30M
Net Income Common Stockholders
-18.01M-16.64M-70.57M-26.86M-25.07M-36.05M
Balance SheetCash, Cash Equivalents and Short-Term Investments
12.22M2.87M3.56M15.86M15.04M23.91M
Total Assets
48.51M27.77M30.74M16.84M21.04M33.44M
Total Debt
139.00K1.79M372.00K124.17K2.26M4.88M
Net Debt
-12.08M-1.08M-3.19M-15.73M-12.78M-19.02M
Total Liabilities
12.65M16.01M9.54M7.58M7.37M12.29M
Stockholders Equity
35.86M11.76M21.19M9.26M13.67M21.15M
Cash FlowFree Cash Flow
-9.72M-9.34M-20.70M-22.59M-27.89M-28.37M
Operating Cash Flow
-9.67M-9.27M-20.62M-22.57M-27.63M-28.30M
Investing Cash Flow
-55.00K-67.00K-61.00K21.00K3.80M15.93M
Financing Cash Flow
8.68M8.65M8.39M23.36M14.96M21.69M

Catheter Precision Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.36
Price Trends
50DMA
0.28
Positive
100DMA
0.33
Positive
200DMA
0.41
Negative
Market Momentum
MACD
0.03
Negative
RSI
55.93
Neutral
STOCH
44.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.28, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 55.93 is Neutral, neither overbought nor oversold. The STOCH value of 44.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTAK.

Catheter Precision Risk Analysis

Catheter Precision disclosed 78 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Catheter Precision Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$3.89M-163.47%-100.00%78.91%
54
Neutral
$5.38B3.27-45.10%3.30%16.81%0.02%
49
Neutral
$4.60M-136.26%9.57%10.03%
46
Neutral
$12.60M-450.47%9.47%81.37%
45
Neutral
$1.33M-440.77%-1.21%93.72%
42
Neutral
$8.20M-155.20%9.90%94.56%
37
Underperform
$6.01M-120.16%-7.74%93.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VTAK
Catheter Precision
0.36
-4.84
-93.08%
NUWE
Nuwellis
0.28
-6.20
-95.68%
SINT
Sintx Technologies
3.27
-2.79
-46.04%
RSLS
ReShape Lifesciences
2.52
-295.89
-99.16%
VVOS
Vivos Therapeutics
2.14
0.09
4.39%
HSCS
Heart Test Laboratories, Inc.
3.57
-1.72
-32.51%

Catheter Precision Corporate Events

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Catheter Precision’s LockeT Sales Surge in Q2 2025
Positive
Jun 13, 2025

Catheter Precision announced that its LockeT product sales for Q2 2025 are on track to be the highest to date, surpassing Q2 2024 sales by over $84,000. The company has secured a new distributor in Italy and is seeking additional distributors in Spain, Portugal, and the UK, aiming to expand its European footprint. Three U.S. hospitals are expected to issue significant purchase orders for LockeT by the end of 2025, indicating strong market interest. The CE Mark approval for LockeT facilitates its sales in Europe, and a live demonstration is scheduled in Italy to boost product awareness.

Private Placements and FinancingShareholder Meetings
Catheter Precision Approves Warrant Issuance to Ladenburg
Neutral
Jun 9, 2025

On June 5, 2025, Catheter Precision, Inc.’s Board of Directors approved a warrant issuance to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to the company’s pipe financing closed on May 12, 2025. This warrant allows the purchase of 257,143 shares at $0.5424 per share, pending stockholder approval at the annual meeting on July 25, 2025. The warrant will expire on June 6, 2030, and neither it nor the underlying shares have been registered under the Securities Act of 1933.

Executive/Board Changes
Catheter Precision Announces CCO Departure and Leadership Change
Negative
Jun 6, 2025

On June 2, 2025, Catheter Precision, Inc. announced the discontinuation of employment for their Chief Commercial Officer, Marie-Claude Jacques. Executive Chairman and CEO David Jenkins will temporarily assume the role until a new replacement is found, which may impact the company’s commercial operations and leadership dynamics.

Private Placements and Financing
Catheter Precision Announces New Common Stock Offering
Negative
May 30, 2025

Catheter Precision has announced a new offering of common stock that will result in dilution for new investors. As of March 31, 2025, the net tangible book value per share was $(1.71), and after adjustments, it is expected to be $(0.95) per share. This represents an immediate increase in value for existing shareholders but a substantial dilution for new investors purchasing at the assumed offering price of $0.30 per share. The company may also raise additional capital, which could lead to further dilution.

Private Placements and Financing
Catheter Precision Enters Market Offering Agreement
Neutral
May 19, 2025

On May 19, 2025, Catheter Precision, Inc. entered into an At Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to potentially sell up to $1.3 million of its common stock. The proceeds from any sales will be used to fund operations and working capital. Ladenburg will sell shares based on the company’s instructions, adhering to legal and exchange rules. The agreement can be terminated by either party with notice, and Ladenburg will receive a 3% commission on sales.

Private Placements and FinancingShareholder Meetings
Catheter Precision Enters Securities Purchase Agreement
Neutral
May 13, 2025

On May 12, 2025, Catheter Precision, Inc. entered into a Securities Purchase Agreement with three investors, selling 1.5 million shares of its Series B Convertible Preferred Stock and issuing an additional 1.5 million shares as consideration for existing senior secured Convertible Promissory Notes of QHSLab, Inc. The company has reserved up to 8,574,000 shares of common stock for conversion and issued Series L warrants for purchasing up to 4,285,716 shares of common stock. The conversion and exercise of these securities are subject to stockholder approval, which the company plans to seek at its Annual Meeting on July 25, 2025. The Series B Convertible Preferred Stock has a fixed conversion price of $0.35 per share, while the Series L warrants have a 5 ½ year term and are exercisable at $0.50 per share. The securities offering was conducted under an exemption from registration requirements, and the company intends to register the shares for resale by May 27, 2025.

M&A TransactionsBusiness Operations and Strategy
Catheter Precision Finalizes Strategic Cardiac Acquisition
Neutral
May 8, 2025

In February 2025, Catheter Precision, Inc. formed a subsidiary, Cardionomix, Inc., to acquire assets from Cardionomic, Inc., which had ceased operations. On April 18, 2025, Cardionomix entered into an agreement to purchase assets related to a late-stage treatment for acute decompensated heart failure, including patents and trademarks for the Cardiac Pulmonary Nerve Simulation System. The acquisition was finalized on May 5, 2025, with Catheter Precision issuing 1,000,000 restricted shares and Cardionomix providing a $1.5 million promissory note. This strategic acquisition aims to enhance Catheter Precision’s portfolio in cardiac care, although it involves financial obligations and potential equity dilution for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.